Literature DB >> 26264572

Effects on the tumor specific growth factor and tumor necrosis factor α in rats' precancerous lesion of primary hepatocellular carcinoma by direct moxibustion at Ganshu (BL 18) acupoint.

Pei Wang1, Jiang Zhu1,2, Xi-Liang Xie3, Ming-He Sui1, Qiu-Ju Zhang4, Wen-Rui Jia1, Si-Yuan Xin5, Yang Liu1, Zhong-Wei Hou6.   

Abstract

OBJECTIVE: To investigate the effect of direct moxibustion at Ganshu (BL18) on the serum concentrations of tumor specific growth factor (TSGF) and tumor necrosis factor α (TNF-α) in a rat model with precancerous lesion of primary hepatocellular carcinoma (HCC), so as to explore the mechanism of moxibustion underlying improvement of HCC.
METHODS: Sixty male Wistar rats were randomly divided into control group (n=10), model group (n=20), prevention group 1 (n=15) and prevention group 2 (n=15). The normal rats were injected with physiological saline as blank control. At the same time, the rats of other three groups were injected with diethylnitrosamine to establish the HCC model. Direct moxibustion with grain-sized moxa was applied to bilateral Ganshu acupoint of the rats in the prevention group 1 (1 treatment course, 20 days) and prevention group 2 (2 treatment courses, 40 days), 5 doses for each acupoint, 0.5 mg/dose, once every other day. At each time point (before model establishment, the end of 1st course prevention, the end of 2nd course prevention and the end of model establishment), serum levels of TSGF and TNF-α were detected using enzyme-linked immunosorbent assay.
RESULTS: Compared with the control group, there was a remarkably increase of serum TSGF and TNF-α contents in the model group at the end of the experiment (P<0.05). At the end of the 1st course of direct moxibustion, the contents of serum TSGF and TNF-α of rats in the prevention group 1 were significantly increased compared with that of the model group (P<0.05). At the end of the 2nd course of direct moxibustion, serum TSGF and TNF-α levels of rats in the model group were higher than the normal group with significantly difference (P<0.05), and the levels of TSGF and TNF-α in the prevention group 2 were significantly reduced in comparison with the model group (P<0.05).
CONCLUSION: It was possible that direct moxibustion could inhibit precancerous lesion and postpone hepatocarcinogenesis, and the therapeutic effect of two courses were better than one course.

Entities:  

Keywords:  Chinese medicine; diethylnitrosamine; direct moxibustion; hepatocellular carcinoma; tumor necrosis factor α; tumor specific growth factor

Mesh:

Substances:

Year:  2015        PMID: 26264572     DOI: 10.1007/s11655-015-2157-7

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  10 in total

Review 1.  Mouse models of transforming growth factor beta impact in breast development and cancer.

Authors:  R Serra; M R Crowley
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

Review 2.  Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers.

Authors:  E M V de Cuba; R Kwakman; M van Egmond; L J W Bosch; H J Bonjer; G A Meijer; E A te Velde
Journal:  Virchows Arch       Date:  2012-07-24       Impact factor: 4.064

Review 3.  Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?

Authors:  L Benhaim; F Loupakis; M J Labonte; H J Lenz
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-09       Impact factor: 7.027

4.  Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock.

Authors:  Jose Francisco Garcia-Lazaro; Florian Thieringer; Stefan Lüth; Piotr Czochra; Erik Meyer; Isaias Balderas Renteria; Peter R Galle; Ansgar W Lohse; Johannes Herkel; Stephan Kanzler
Journal:  Immunol Lett       Date:  2005-11-15       Impact factor: 3.685

Review 5.  Hepatocellular carcinoma: an Asian perspective.

Authors:  E K Teo; K M Fock
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

Review 6.  Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.

Authors:  T Efferth
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 7.  Epidemiology and natural history of hepatocellular carcinoma.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-02       Impact factor: 3.043

8.  Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China.

Authors:  Dong-Sheng Yu; Xin-En Huang; Jian-Nong Zhou
Journal:  Asian Pac J Cancer Prev       Date:  2012

9.  Fibroproliferation in liver disease: role of monocyte factors.

Authors:  T C Peterson; R A Isbrucker
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

Review 10.  Tumor markers in clinical practice: a review focusing on common solid cancers.

Authors:  Michael J Duffy
Journal:  Med Princ Pract       Date:  2012-05-15       Impact factor: 1.927

  10 in total
  3 in total

1.  Effect of moxibustion on quality of life after chemotherapy in patients with the malignant tumor: A protocol for systematic review and meta analysis.

Authors:  Dan Tao; Jingyu Xu; Shuyuan Zou; Yanfu Tan; Shuangchun Ai
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

2.  Grain-Sized Moxibustion Heightens the AntiTumor Effect of Cyclophosphamide in Hepa1-6 Bearing Mice.

Authors:  Tao Zhu; Yanzhu Ma; Jianyun Wang; Xiaolin Chen; Jianhao Li; Liqiang Meng; Yuduo Hou; Yanting Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-08       Impact factor: 2.650

3.  Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer.

Authors:  Yang Cheng; Tianyang Chen; Jianjie Chen
Journal:  J Cancer       Date:  2020-10-22       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.